Monday April 13, 2026

Key Takeaways

• Stryker acquires Amplitude Vascular, adding intravascular lithotripsy to its portfolio.
• Gilead's $5 B purchase of Tubulis highlights premium value of delivery platforms.
• Monteris raises $28 M to expand NeuroBlate and U.S. commercial footprint.
• Luminai's $38 M Series B funds AI infrastructure for health system workflow efficiency.

Pulse Analysis

The medtech landscape is experiencing a convergence of strategic M&A and venture‑backed growth, especially in neurovascular and AI‑focused solutions. Stryker’s purchase of Amplitude Vascular positions the company to address calcified peripheral artery disease with lithotripsy, a technology that can reduce procedural time and improve outcomes. Meanwhile, Gilead’s $5 billion bid for Tubulis signals that pharmaceutical giants are willing to pay a premium for platforms that combine drug delivery with robust clinical data, a trend that blurs the line between devices and therapeutics.

Investors are rewarding companies that can demonstrate both procedural differentiation and a clear evidence generation pathway. Monteris Medical’s $28 million growth round will fund the expansion of its NeuroBlate system, enabling broader U.S. adoption through expanded clinical trials and sales infrastructure. Luminai’s $38 million Series B underscores the rising demand for AI tools that streamline health‑system operations, offering measurable labor savings and workflow consistency. These capital infusions reflect confidence that data‑rich, outcome‑driven technologies will secure payer reimbursement and sustain long‑term revenue growth.

For industry leaders, the key takeaway is the growing importance of aligning product claims with verifiable evidence. The Pathway’s own study showing 86 % of medtech teams overstate their data highlights a risk area during due diligence and partnership negotiations. As health systems prioritize tools that deliver operational efficiency and generate actionable data—evident in ProSomnus’s monitoring‑enhanced sleep apnea device and Miracell’s regenerative cell platform—companies that can substantiate their value proposition will attract the next wave of strategic partnerships and funding.